Declaration of Voting Results & Voting Rights Announcements • Oct 7, 2013
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Paris, October 7, 2013 – Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority):
| Date | Total number of outstanding shares |
Total number of voting rights |
|---|---|---|
| September 30, 2013 | 20, 656,675 | Theoretical number of voting rights: 20, 656,675 (including treasury shares) Number of real voting rights: 20,629,268 (without treasury shares) |
Dedicated to Specialty Pharma and Orphan products in cancer treatment and in supportive care, with a focus on drug resistance, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and USA; the products' commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com.
Judith Gréciet, CEO Caroline Carmagnol Tel.: +33 1 45 58 76 01 Tel.: +33 6 64 18 99 59 Judith.grecie[email protected] [email protected]
Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.